Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142

HIV Clinical Trials

Volumn 14, Issue 5, 2013, Pages 224-234

  Huang, Jeannie ^a   Hughes, Michael ^b   Riddler, Sharon ^c   Haubrich, Richard ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

antiretroviral therapy; bone density; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR ALAFENAMIDE; TENOFOVIR DISOPROXIL; VIRUS RNA;

ADULT; ARTICLE; BODY COMPOSITION; BONE DENSITY; BONE MINERAL; CD4 LYMPHOCYTE COUNT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FRACTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZATION; SIDE EFFECT; TREATMENT OUTCOME; VIRUS LOAD;

ANTIRETROVIRAL THERAPY; BONE DENSITY; HIV;

ADULT; ANTI-HIV AGENTS; BONE DENSITY; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84886487823     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1405-224     Document Type: Article

References (47)

1. Rivas P, Gorgolas M, Garcia-Delgado R, Diaz-Curiel M, Goyenechea A, Fernandez-Guerrero ML. Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir. HIV Med. 2008;9(2):89-95. (Pubitemid 351228131)
2. Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, da Silva BA. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defi c Syndr. 2009;51(5):554-561.
3. Gallant JE, Staszewski S, Pozniak AL, et al. Effi cacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. JAMA. 2004;292(2):191-201. (Pubitemid 38917996)
4. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavirritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203(12):1791-1801.
5. Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS. 2009;23(9):1109-1118.
6. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358(20):2095-2106. (Pubitemid 351679596)
7. Duvivier C, Kolta S, Assoumou L, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS (Lond). 2009;23(7):817-824.
8. Cassetti I, Madruga JV, Suleiman JM, et al. The safety and effi cacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials. 2007;8(3):164-172. (Pubitemid 47121761)
9. Yin MT, Shane E. Low bone-mineral density in patients with HIV: Pathogenesis and clinical signifi cance. Curr Opin Endocrinol Diabetes. 2006;13(6):497-502. (Pubitemid 44691254)
10. Jacobson DL, Spiegelman D, Knox TK, Wilson IB. Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr. 2008;49(3):298-308.
11. Pan G, Wu X, McKenna MA, Feng X, Nagy TR, McDonald JM. AZT enhances osteoclastogenesis and bone loss. AIDS Res Hum Retroviruses. 2004;20(6):608-620. (Pubitemid 38813658)
12. Zuccotti G, Vigano A, Gabiano C, et al. Antiretroviral therapy and bone mineral measurements in HIV-infected youths. Bone. 2010;46(6):1633-1638.
13. McComsey GA, Lo Re V, 3rd, O'Riordan M, et al. Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIVinfected subjects: A randomized, controlled study. Clin Infect Dis. 2008;46(8):1290-1296. (Pubitemid 351589916)
14. van Vonderen MG, Lips P, van Agtmael MA, et al. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS. 2009;23(11):1367-1376.
15. Jain RG, Lenhard JM. Select HIV protease inhibitors alter bone and fat metabolism ex vivo. J Biol Chem. 2002;277(22):19247-19250. (Pubitemid 34967427)
16. Fakruddin JM, Laurence J. HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. J Biol Chem. 2003;278(48):48251-48258. (Pubitemid 37523280)
17. Grigsby IF, Pham L, Mansky LM, Gopalakrishnan R, Mansky KC. Tenofovir-associated bone density loss. Ther Clin Risk Manag. 2010;6:41-47.
18. Looker AC, Melton LJ 3rd, Harris T, Borrud L, Shepherd J, McGowan J. Age, gender, and race/ethnic differences in total body and subregional bone density. Osteoporos Int. 2009;20(7):1141-1149.
19. Hui SL, Slemenda CW, Johnston CC, Appledorn CR. Effects of age and menopause on vertebral bone density. Bone Mineral. 1987;2(2):141-146. (Pubitemid 17119423)
20. Nuti R, Martini G. Effects of age and menopause on bone density of entire skeleton in healthy and osteoporotic women. Osteoporos Int. 1993;3(2):59-65. (Pubitemid 23088897)
21. Dolan SE, Kanter JR, Grinspoon S. Longitudinal analysis of bone density in human immunodefi ciency virus-infected women. J Clin Endocrinol Metabol. 2006;91(8):2938-2945. (Pubitemid 44271739)
22. Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodefi ciency virus-infected individuals. Clin Infect Dis. 2003;36(4):482-490. (Pubitemid 36241317)
23. Dolan SE, Huang JS, Killilea KM, Sullivan MP, Aliabadi N, Grinspoon S. Reduced bone density in HIV-infected women. AIDS (Lond). 2004;18(3):475-483. (Pubitemid 38365875)
24. Fausto A, Bongiovanni M, Cicconi P, et al. Potential predictive factors of osteoporosis in HIV-positive subjects. Bone. 2006;38(6):893-897. (Pubitemid 44500653)
25. Grijsen ML, Vrouenraets SM, Steingrover R, et al. High prevalence of reduced bone mineral density in primary HIV-1-infected men. AIDS (Lond). 2010;24(14):2233-2238.
26. Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS (Lond). 2003;17(13):1917-1923. (Pubitemid 37070277)
27. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: A meta-analytic review. AIDS (Lond). 2006;20(17):2165-2174. (Pubitemid 44684707)
28. Yong MK, Elliott JH, Woolley IJ, Hoy JF. Low CD4 count is associated with an increased risk of fragility fracture in HIV-infected patients. J Acquir Immune Defic Syndr. 2011;57(3):205-210.
29. Thomas J, Doherty SM. HIV infection-a risk factor for osteoporosis. J Acquir Immune Defic Syndr. 2003;33(3):281-291. (Pubitemid 36859053)
30. Cotter EJ, Ip HS, Powderly WG, Doran PP. Mechanism of HIV protein induced modulation of mesenchymal stem cell osteogenic differentiation. BMC Musculoskel Disord. 2008;9:33.
31. Gibellini D, De Crignis E, Ponti C, et al. HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFalpha activation. J Med Virol. 2008;80(9):1507-1514.
32. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2008.
33. Lundgren JD, Battegay M, Behrens G, et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med. 2008;9(2):72-81. (Pubitemid 351232645)
34. Young B, Dao CN, Buchacz K, Baker R, Brooks JT. Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis. 2011;52(8):1061- 1068.
35. McComsey GA, Tebas P, Shane E, et al. Bone disease in HIV infection: A practical review and recommendations for HIV care providers. Clin Infect Dis. 2010;51(8):937-946.
36. Franck H, Munz M. Total body and regional bone mineral densitometry (BMD) and soft tissue measurements: Correlations of BMD parameter to lumbar spine and hip. Calcif Tissue Int. 2000;67(2):111-115. (Pubitemid 30614639)
37. Boyanov M. Estimation of lumbar spine bone mineral density by dual-energy X-ray absorptiometry: Standard anteroposterior scans vs sub-regional analyses of wholebody scans. Br J Radiol. 2008;81(968):637-642.
38. Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS (Lond). 2012;26(7):825-831.
39. Huang JS, Wilkie SJ, Sullivan MP, Grinspoon S. Reduced bone density in androgen-defi cient women with acquired immune defi ciency syndrome wasting. J Clin Endocrinol Metabol. 2001;86(8):3533-3539. (Pubitemid 32755940)
40. Teichmann J, Lange U, Discher T, Lohmeyer J, Stracke H, Bretzel RG. Bone mineral density in human immunodefi-ciency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (HAART). Eur J Med Res. 2009;14(2):59-64.
41. Bang UC, Shakar SA, Hitz MF, et al. Deficiency of 25-hydroxyvitamin D in male HIV-positive patients: A descriptive cross-sectional study. Scand J Infect Dis. 2010;42(4):306-310.
42. Goicoechea M, Rieg G, Dube M, et al. Faster early viral decline with raltegravir (RAL) + lopinavir/ritonavir (LPV/r) vs. efavirenz (EFV)/tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) in antiretroviral-naive patients: CCTG 589. Paper presented at: XVIII International AIDS Conference; 2010; Vienna, Austria.
43. Taiwo B, Zheng L, Gallien S, et al. Effi cacy of a nucleosidesparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS. 2011;25(17):2113-2122.
44. Burgos J, Crespo M, Falco V, et al. Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen. J Antimicrob Chemother. 2012;67(6):1453-1458.
45. Patterson P, Magneres C, Sued O, et al. A phase 4, singlearm, open-label, pilot study of maraviroc, raltegravir and darunavir/r in HIV-1 adults with triple class failure: TERCETO study. J Int AIDS Soc. 2012;15(6):18268.
46. Cenderello G, Penco G, Pontali E, Feasi M, Cassola G. Safety and efficacy of a raltegravir-based dual antiretroviral therapy in clinical practice. J Int AIDS Soc. 2012;15(6):18353.
47. Zolopa A, Ortiz R, Sax P, et al. Comparative study of tenofovir alafenamide vs. tenofovir disoproxil fumarate, each with elvitegravir, cobicistat, and emtricitabine, for HIV treatment. Paper presented at: 20th Conference on Retroviruses and Opportunistic Infections; 2013; Atlanta, GA.